Bridin Murnion
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bridin Murnion has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Suzanne Nielsen
Monash Addiction Research Centre Monash University Melbourne Australia
7 shared publications - Kieron Rooney
University of Sydney
5 shared publications - Jana Stojanova
Department of Clinical Pharmacology and Toxicology St Vincent's Hospital Sydney Australia
4 shared publications - Jonathan Brett
Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health UNSW Sydney Sydney Australia
4 shared publications - Richard Osborne Day
St Vincent’s Clinical Campus, School of Medicine, St Vincent’s Hospital, University of New South Wales, Darlinghurst, Australia
4 shared publications - Amy Gray McNeilage
Sydney Medical School, Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
3 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-11
Stakeholder Perceptions for the Development of Gabapentinoid Deprescribing Clinical Guideline: A Functional Role Theory Approach
Background: Gabapentinoids are increasingly prescribed for a range of indications, despite growing concerns about their long-term safety and limited evidence of effectiveness for off-label use. While deprescribing is a recognised strategy to mitigate medication-related harm, clear tapering guidance for gabapentinoids is lacking. Objective: To explore consumer and healthcare professional (HCP) perceptions of the need and scope of a gabapentinoid deprescribing clinical guideline. Design: An exploratory qualitative study was conducted using semi-structured interviews. Participants: A total of 25 participants were interviewed, comprising 13 consumers and 12 HCPs (e.g. general practitioners, pharmacists, neurologists). Approach: Reflexive thematic analysis was applied, guided by functional role theory, to examine stakeholders’ perceptions of their own and others’ roles in gabapentinoid deprescribing and expectations, to inform subsequent guideline development. Key Results: Gabapentinoid deprescribing was viewed by stakeholders as a holistic, system-wide activity involving not only prescribers but also allied health professionals. All stakeholders identified a need for guideline recommendations that reflect this complexity and inclusivity. Consumers experienced fragmented care, partly because both they and GPs were left to navigate the deprescribing process without formal guidance. HCPs identified divided responsibilities between prescribers initiating and those tasked with deprescribing, leading to subsequent challenges, particularly for GPs in managing long-term effects. HCPs valued promoting a ‘prescribing continuum’ over adopting dichotomous roles that separate prescribing from deprescribing. Consumers, including carers, expressed a desire to be central in both the development of guidelines and the process of deprescribing. Stakeholders articulated the need for a deprescribing guideline that addresses the realities of gabapentinoid use in practice. Conclusion: Gabapentinoid deprescribing guidelines should be co-designed with consumers and inclusive of diverse HCPs, addressing role ambiguity and supporting continuity of care. Consumers expressed desire to be actively involved in guideline development and HCPs recognised the need for coordinated care and shared accountability across the healthcare system.
- 3 November 2026
- Published by Springer Nature in Journal of General Internal Medicine
- p. 1-11
Open AccessStakeholder Perceptions for the Development of Gabapentinoid Deprescribing Clinical Guideline: A Functional Role Theory Approach
Background: Gabapentinoids are increasingly prescribed for a range of indications, despite growing concerns about their long-term safety and limited evidence of effectiveness for off-label use. While deprescribing is a recognised strategy to mitigate medication-related harm, clear tapering guidance for gabapentinoids is lacking. Objective: To explore consumer and healthcare professional (HCP) perceptions of the need and scope of a gabapentinoid deprescribing clinical guideline. Design: An exploratory qualitative study was conducted using semi-structured interviews. Participants: A total of 25 participants were interviewed, comprising 13 consumers and 12 HCPs (e.g. general practitioners, pharmacists, neurologists). Approach: Reflexive thematic analysis was applied, guided by functional role theory, to examine stakeholders’ perceptions of their own and others’ roles in gabapentinoid deprescribing and expectations, to inform subsequent guideline development. Key Results: Gabapentinoid deprescribing was viewed by stakeholders as a holistic, system-wide activity involving not only prescribers but also allied health professionals. All stakeholders identified a need for guideline recommendations that reflect this complexity and inclusivity. Consumers experienced fragmented care, partly because both they and GPs were left to navigate the deprescribing process without formal guidance. HCPs identified divided responsibilities between prescribers initiating and those tasked with deprescribing, leading to subsequent challenges, particularly for GPs in managing long-term effects. HCPs valued promoting a ‘prescribing continuum’ over adopting dichotomous roles that separate prescribing from deprescribing. Consumers, including carers, expressed a desire to be central in both the development of guidelines and the process of deprescribing. Stakeholders articulated the need for a deprescribing guideline that addresses the realities of gabapentinoid use in practice. Conclusion: Gabapentinoid deprescribing guidelines should be co-designed with consumers and inclusive of diverse HCPs, addressing role ambiguity and supporting continuity of care. Consumers expressed desire to be actively involved in guideline development and HCPs recognised the need for coordinated care and shared accountability across the healthcare system.
- Open Access
- 11 May 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (6) , e70150
Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report
Background: Drug interactions involving immunosuppressants can compromise transplant outcomes. Although repeated ketamine administration induces hepatic enzymes in experimental models, clinical reports of induced clearance of cytochrome P450 (CYP) substrates are lacking. Continuous subcutaneous ketamine infusions are increasingly used for acute pain management. We present a case of difficult‐to‐maintain tacrolimus and sirolimus concentrations in the context of subcutaneous ketamine infusion for acute pain management. Methods: A 55‐year‐old male heart transplant recipient received continuous subcutaneous ketamine (5.2–10.4 mg/h) for pain management following lower limb thrombectomy. Tacrolimus and sirolimus concentrations were monitored throughout hospitalization and rehabilitation. Population pharmacokinetic modeling with Bayesian estimation characterized temporal clearance changes, incorporating inter‐occasion variability across six periods (pre‐, during‐, and weekly post‐ketamine administration for 4 weeks). Results: Following ketamine initiation, tacrolimus and sirolimus concentrations remained subtherapeutic despite dose escalations of 1.8‐fold and 5‐fold, respectively. Pharmacokinetic modeling revealed approximately 2‐fold clearance increases during ketamine administration, peaking 1 week after initiation. Following ketamine discontinuation, tacrolimus and sirolimus concentrations progressively increased over 3 weeks, consistent with enzyme induction and recovery. Drug Interaction Probability Scale assessment indicated probable interaction (score + 5). Brief concomitant flucloxacillin use may have contributed to the observed changes. Conclusions: This case provides preliminary evidence of potential interaction between ketamine and CYP3A4‐metabolized immunosuppressants. Clinicians should consider increased therapeutic drug monitoring when using ketamine with narrow therapeutic range medications, continuing approximately 3 weeks post‐discontinuation.
- 11 May 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (6) , e70150
Open AccessContinuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report
Background: Drug interactions involving immunosuppressants can compromise transplant outcomes. Although repeated ketamine administration induces hepatic enzymes in experimental models, clinical reports of induced clearance of cytochrome P450 (CYP) substrates are lacking. Continuous subcutaneous ketamine infusions are increasingly used for acute pain management. We present a case of difficult‐to‐maintain tacrolimus and sirolimus concentrations in the context of subcutaneous ketamine infusion for acute pain management. Methods: A 55‐year‐old male heart transplant recipient received continuous subcutaneous ketamine (5.2–10.4 mg/h) for pain management following lower limb thrombectomy. Tacrolimus and sirolimus concentrations were monitored throughout hospitalization and rehabilitation. Population pharmacokinetic modeling with Bayesian estimation characterized temporal clearance changes, incorporating inter‐occasion variability across six periods (pre‐, during‐, and weekly post‐ketamine administration for 4 weeks). Results: Following ketamine initiation, tacrolimus and sirolimus concentrations remained subtherapeutic despite dose escalations of 1.8‐fold and 5‐fold, respectively. Pharmacokinetic modeling revealed approximately 2‐fold clearance increases during ketamine administration, peaking 1 week after initiation. Following ketamine discontinuation, tacrolimus and sirolimus concentrations progressively increased over 3 weeks, consistent with enzyme induction and recovery. Drug Interaction Probability Scale assessment indicated probable interaction (score + 5). Brief concomitant flucloxacillin use may have contributed to the observed changes. Conclusions: This case provides preliminary evidence of potential interaction between ketamine and CYP3A4‐metabolized immunosuppressants. Clinicians should consider increased therapeutic drug monitoring when using ketamine with narrow therapeutic range medications, continuing approximately 3 weeks post‐discontinuation.
- 4 December 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (4) , 1204-1212
Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit
Aim: To evaluate quality use of medicines (QUM) in patients admitted to the Psychiatric Alcohol and Non‐Prescription Drug Assessment (PANDA) Unit through analysis of polypharmacy risk, prescribing safety indicators and national QUM indicators. Methods: Retrospective review of electronic medical records for 787 patients (1245 episodes) admitted to PANDA Unit, St Vincent's Hospital Sydney, November 2020–December 2021. We assessed polypharmacy risk using NSW Therapeutic Advisory Group's Inappropriate Polypharmacy Risk Assessment Tool, evaluated nine prescribing safety indicators (PSIs) and assessed four national quality use of medicines indicators (NQUMIs) in a randomly selected subset of 103 patients. Results: Mean age was 40.2 years; 67.2% were male. Alcohol‐related diagnoses comprised 32.1% of presentations. Medium‐risk (43.5%) and high‐risk (37.2%) polypharmacy were prevalent, largely reflecting protocol‐driven prescribing for acute presentations. Co‐prescription of QT‐prolonging drugs with antipsychotics affected 17.2% of patients, with 64.7% associated with rapid sedation protocols; only one case of potential QT prolongation was documented. Major gaps were identified in medication reconciliation (40.8% had documented medication history) and discharge documentation (13.1% of discharge summaries contained complete medication information). Patients experiencing homelessness demonstrated poorer outcomes across all QUM indicators, with no discharge summaries meeting quality standards. Conclusion: While PANDA demonstrated appropriate protocol‐driven prescribing for acute psychiatric presentations, substantial gaps in medication reconciliation and discharge communication highlight challenges in care transitions for priority populations. Standard polypharmacy and prescribing safety indicators may require adaptation for acute psychiatric settings to distinguish appropriate acute prescribing from potentially inappropriate practices.
- 4 December 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (4) , 1204-1212
Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit
Aim: To evaluate quality use of medicines (QUM) in patients admitted to the Psychiatric Alcohol and Non‐Prescription Drug Assessment (PANDA) Unit through analysis of polypharmacy risk, prescribing safety indicators and national QUM indicators. Methods: Retrospective review of electronic medical records for 787 patients (1245 episodes) admitted to PANDA Unit, St Vincent's Hospital Sydney, November 2020–December 2021. We assessed polypharmacy risk using NSW Therapeutic Advisory Group's Inappropriate Polypharmacy Risk Assessment Tool, evaluated nine prescribing safety indicators (PSIs) and assessed four national quality use of medicines indicators (NQUMIs) in a randomly selected subset of 103 patients. Results: Mean age was 40.2 years; 67.2% were male. Alcohol‐related diagnoses comprised 32.1% of presentations. Medium‐risk (43.5%) and high‐risk (37.2%) polypharmacy were prevalent, largely reflecting protocol‐driven prescribing for acute presentations. Co‐prescription of QT‐prolonging drugs with antipsychotics affected 17.2% of patients, with 64.7% associated with rapid sedation protocols; only one case of potential QT prolongation was documented. Major gaps were identified in medication reconciliation (40.8% had documented medication history) and discharge documentation (13.1% of discharge summaries contained complete medication information). Patients experiencing homelessness demonstrated poorer outcomes across all QUM indicators, with no discharge summaries meeting quality standards. Conclusion: While PANDA demonstrated appropriate protocol‐driven prescribing for acute psychiatric presentations, substantial gaps in medication reconciliation and discharge communication highlight challenges in care transitions for priority populations. Standard polypharmacy and prescribing safety indicators may require adaptation for acute psychiatric settings to distinguish appropriate acute prescribing from potentially inappropriate practices.
- Open Access
- 1 December 2025
- Published by KEAI Publishing in Advanced Exercise and Health Science
- Vol. 2 (4) , 293-300
Exercise is therapy: A cross-sectional study evaluation of the impact of exercise on affect, arousal and distress in an inpatient mental health service
- 1 December 2025
- Published by KEAI Publishing in Advanced Exercise and Health Science
- Vol. 2 (4) , 293-300
Open AccessExercise is therapy: A cross-sectional study evaluation of the impact of exercise on affect, arousal and distress in an inpatient mental health service
- Open Access
- 26 September 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (2) , 545-555
Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database
Aims: Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals. Methods: We conducted disproportionality analyses using case reports involving adverse events related to dependence, withdrawal, suicidality and psychosis, submitted to Australia's Therapeutic Goods Administration between 2005 and 2024. Reporting odds ratios (RORs) were calculated to determine whether these adverse events were disproportionately reported for pregabalin compared to all other drugs in the database and to an active comparator group of other neuropathic pain drugs (gabapentin, duloxetine and amitriptyline). Results: Compared to all other drugs in the database, pregabalin showed strong signals of disproportionate reporting for drug abuse and dependence (ROR = 13.53, 95% confidence interval [CI]: 12.12, 15.10), drug withdrawal (ROR = 6.76, 95% CI: 4.99, 9.15), suicide and self‐injury (ROR = 12.40, 95% CI: 10.71, 14.36), and psychosis and psychotic disorders (ROR = 5.81, 95% CI: 4.99, 6.76). When compared to other neuropathic pain drugs, the signal of disproportionate reporting remained for drug abuse and dependence (ROR = 1.38, 95% CI: 1.17, 1.62) and psychosis and psychotic disorders (ROR = 1.26, 95% CI: 1.002, 1.57), albeit with less pronounced effects. Conclusions: Adverse events related to drug dependence and psychosis are reported to the Australian pharmacovigilance database at a higher rate for pregabalin compared to other drugs, including other neuropathic pain drugs, signalling a potential concern that warrants further investigation.
- 26 September 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (2) , 545-555
Open AccessPregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database
Aims: Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals. Methods: We conducted disproportionality analyses using case reports involving adverse events related to dependence, withdrawal, suicidality and psychosis, submitted to Australia's Therapeutic Goods Administration between 2005 and 2024. Reporting odds ratios (RORs) were calculated to determine whether these adverse events were disproportionately reported for pregabalin compared to all other drugs in the database and to an active comparator group of other neuropathic pain drugs (gabapentin, duloxetine and amitriptyline). Results: Compared to all other drugs in the database, pregabalin showed strong signals of disproportionate reporting for drug abuse and dependence (ROR = 13.53, 95% confidence interval [CI]: 12.12, 15.10), drug withdrawal (ROR = 6.76, 95% CI: 4.99, 9.15), suicide and self‐injury (ROR = 12.40, 95% CI: 10.71, 14.36), and psychosis and psychotic disorders (ROR = 5.81, 95% CI: 4.99, 6.76). When compared to other neuropathic pain drugs, the signal of disproportionate reporting remained for drug abuse and dependence (ROR = 1.38, 95% CI: 1.17, 1.62) and psychosis and psychotic disorders (ROR = 1.26, 95% CI: 1.002, 1.57), albeit with less pronounced effects. Conclusions: Adverse events related to drug dependence and psychosis are reported to the Australian pharmacovigilance database at a higher rate for pregabalin compared to other drugs, including other neuropathic pain drugs, signalling a potential concern that warrants further investigation.
- Open Access
- 2 September 2025
- Published by Wiley in European journal of pain
- Vol. 29 (9) , e70116
Healthcare Practitioner and Other Professionals' Perspectives on Gabapentinoid Misuse and Dependence: A Systematic Review of Qualitative Studies
Background and Objective: The global rise in gabapentinoid prescriptions for chronic pain has been striking. However, this trend has been accompanied by growing concerns about misuse and dependence. This qualitative systematic review aimed to synthesise the perspectives of healthcare practitioners and other professionals on these emerging challenges. Databases and Data Treatment: Six databases (MEDLINE, Scopus, Web of Science, CINAHL, EMBASE, PsycINFO) were searched to May 2025. Eligible studies used qualitative or mixed methods to explore professional views on gabapentinoid misuse or dependence. Studies focusing solely on patient perspectives or therapeutic use were excluded. Methodological quality was assessed using the Critical Appraisal Skills Programme checklist. Data were analysed using thematic synthesis, and confidence in the findings was evaluated using GRADE‐CERQual. Results: After screening 1584 records, 19 original studies were included. Most were conducted in substance use treatment and law enforcement settings, where professionals frequently encounter vulnerable populations and more severe patterns of misuse than in general clinical care. Reported drivers of misuse included polydrug use, opioid substitution, psychological distress and poor access to non‐pharmacological care. Signs of misuse included early refills, dose escalation and reluctance to taper. Professionals described ethical tensions in prescribing and dispensing and proposed harm reduction strategies, including prescriber education, regulatory reform, expanded treatment access and public awareness. Conclusions: Gabapentinoid misuse is shaped by clinical, social and structural factors. Tackling these challenges requires systemic responses that go beyond individual prescribers. Lessons from opioid policy responses should inform balanced, compassionate and evidence‐informed strategies to reduce harm and improve care. Significance Statement: This is the first systematic review to synthesise professional perspectives on gabapentinoid misuse and dependence, drawing on studies from Europe, North America, the Middle East and Africa. Integrating insights from healthcare, law enforcement and policy settings, it reveals the structural drivers behind rising misuse—including opioid regulation, socioeconomic hardship and limited access to alternatives—and highlights gaps in clinical guidance. The findings offer actionable, cross‐sector strategies to support safer prescribing, informed policy and more effective harm reduction.
- 2 September 2025
- Published by Wiley in European journal of pain
- Vol. 29 (9) , e70116
Open AccessHealthcare Practitioner and Other Professionals' Perspectives on Gabapentinoid Misuse and Dependence: A Systematic Review of Qualitative Studies
Background and Objective: The global rise in gabapentinoid prescriptions for chronic pain has been striking. However, this trend has been accompanied by growing concerns about misuse and dependence. This qualitative systematic review aimed to synthesise the perspectives of healthcare practitioners and other professionals on these emerging challenges. Databases and Data Treatment: Six databases (MEDLINE, Scopus, Web of Science, CINAHL, EMBASE, PsycINFO) were searched to May 2025. Eligible studies used qualitative or mixed methods to explore professional views on gabapentinoid misuse or dependence. Studies focusing solely on patient perspectives or therapeutic use were excluded. Methodological quality was assessed using the Critical Appraisal Skills Programme checklist. Data were analysed using thematic synthesis, and confidence in the findings was evaluated using GRADE‐CERQual. Results: After screening 1584 records, 19 original studies were included. Most were conducted in substance use treatment and law enforcement settings, where professionals frequently encounter vulnerable populations and more severe patterns of misuse than in general clinical care. Reported drivers of misuse included polydrug use, opioid substitution, psychological distress and poor access to non‐pharmacological care. Signs of misuse included early refills, dose escalation and reluctance to taper. Professionals described ethical tensions in prescribing and dispensing and proposed harm reduction strategies, including prescriber education, regulatory reform, expanded treatment access and public awareness. Conclusions: Gabapentinoid misuse is shaped by clinical, social and structural factors. Tackling these challenges requires systemic responses that go beyond individual prescribers. Lessons from opioid policy responses should inform balanced, compassionate and evidence‐informed strategies to reduce harm and improve care. Significance Statement: This is the first systematic review to synthesise professional perspectives on gabapentinoid misuse and dependence, drawing on studies from Europe, North America, the Middle East and Africa. Integrating insights from healthcare, law enforcement and policy settings, it reveals the structural drivers behind rising misuse—including opioid regulation, socioeconomic hardship and limited access to alternatives—and highlights gaps in clinical guidance. The findings offer actionable, cross‐sector strategies to support safer prescribing, informed policy and more effective harm reduction.
- Open Access
- 19 May 2025
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 55 (5) , 414-421
Pharmacists' views on the implementation of therapeutic drug monitoring in oncology
Background: There is increasing interest in the potential benefit of therapeutic drug monitoring (TDM) in oncology. However, uptake in Australian hospitals is limited.Aim: This study sought to explore hospital pharmacists' experiences with TDM in oncology, seeking to determine if they could provide insights into barriers and facilitators to its implementation.Method: Hospital oncology/haematology pharmacists (n = 18) from all Australian states participated in semi‐structured interviews. Interviews explored experiences of TDM, and perceived barriers and facilitators to TDM uptake in oncology. Interviews were analysed using an inductive approach to generate themes. Ethical approval was granted by the St. Vincent's Hospital Human Research Ethics Committee (Reference no: 2022/ETH00533) and the study conforms to the Australian National statement on ethical conduct in human research. Informed consent was obtained from all participants via distribution of project information sheets and the completion of written consent forms.Results: Most participants provided care in metropolitan tertiary adult hospitals. They reported that TDM was not used routinely to inform therapy for most oncology drugs, but acknowledged potential benefits, particularly when a concentration–effect relationship is established for efficacy or toxicity. Three themes captured the barriers and facilitators to implementation of TDM in oncology: (1) evidence and knowledge translation, (2) logistics and practicalities, and (3) the clinical team.Conclusion: Pharmacists are keen to integrate TDM in oncology patients. Key factors perceived to influence TDM uptake are evidence, knowledge, and logistics (assay availability, funding, staff). Standardised guidance, complemented by clinical champions and pharmacokinetic expertise within the multidisciplinary team, is needed to provide confidence in changing dosing practices. Improved access to relevant drug assays will ensure result turnaround times support dosing decisions.
- 19 May 2025
- Published by Wiley in Journal of Pharmacy Practice and Research
- Vol. 55 (5) , 414-421
Open AccessPharmacists' views on the implementation of therapeutic drug monitoring in oncology
Background: There is increasing interest in the potential benefit of therapeutic drug monitoring (TDM) in oncology. However, uptake in Australian hospitals is limited.Aim: This study sought to explore hospital pharmacists' experiences with TDM in oncology, seeking to determine if they could provide insights into barriers and facilitators to its implementation.Method: Hospital oncology/haematology pharmacists (n = 18) from all Australian states participated in semi‐structured interviews. Interviews explored experiences of TDM, and perceived barriers and facilitators to TDM uptake in oncology. Interviews were analysed using an inductive approach to generate themes. Ethical approval was granted by the St. Vincent's Hospital Human Research Ethics Committee (Reference no: 2022/ETH00533) and the study conforms to the Australian National statement on ethical conduct in human research. Informed consent was obtained from all participants via distribution of project information sheets and the completion of written consent forms.Results: Most participants provided care in metropolitan tertiary adult hospitals. They reported that TDM was not used routinely to inform therapy for most oncology drugs, but acknowledged potential benefits, particularly when a concentration–effect relationship is established for efficacy or toxicity. Three themes captured the barriers and facilitators to implementation of TDM in oncology: (1) evidence and knowledge translation, (2) logistics and practicalities, and (3) the clinical team.Conclusion: Pharmacists are keen to integrate TDM in oncology patients. Key factors perceived to influence TDM uptake are evidence, knowledge, and logistics (assay availability, funding, staff). Standardised guidance, complemented by clinical champions and pharmacokinetic expertise within the multidisciplinary team, is needed to provide confidence in changing dosing practices. Improved access to relevant drug assays will ensure result turnaround times support dosing decisions.
- 25 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1283-1284
Alternative splicing with CYP3A4*22: Implications for the steroid‐tacrolimus drug interaction
- 25 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1283-1284
Alternative splicing with CYP3A4*22: Implications for the steroid‐tacrolimus drug interaction
- Open Access
- 18 February 2025
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 48 (1) , 23-24
Medicinal Mishap: Propranolol overdose following prescription for anxiety
There is insufficient evidence to support routine use of propranolol or other beta blockers in managing symptoms of anxiety, and they should be used with extreme caution in patients with a history of overdose.
- 18 February 2025
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 48 (1) , 23-24
Open AccessMedicinal Mishap: Propranolol overdose following prescription for anxiety
There is insufficient evidence to support routine use of propranolol or other beta blockers in managing symptoms of anxiety, and they should be used with extreme caution in patients with a history of overdose.
- Open Access
- 10 February 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (3) , 754-758
Integrating routine screening for pregnancy intention and contraceptive use into care of women who use alcohol or other drugs
Introduction: There are high rates of unplanned pregnancy and low rates of contraceptive use in women with substance use disorders. Women who use drugs experience many barriers to health. In addiction treatment services in New South Wales, Australia, patients undergo routine health screening on treatment entry and annually thereafter. An integrated pregnancy and contraceptive screening tool was developed. The aim of this cross‐sectional study was to report the feasibility and preliminary outcomes of this tool.Methods: A pregnancy intention screening (PIS) tool was developed and integrated into the electronic medical record and the annual routine screening. This tool consisted of four yes/no questions about current pregnancy, future pregnancy plans and contraceptive use. Responses to these questions are reported. Descriptive statistics were used to report demographic and outcome data.Results: One hundred women were offered and completed the survey. There were low rates of effective or highly effective contraceptive use (24.5 percent of eligible participants). Seventy‐four percent of participants wanted further information on contraception.Discussion and Conclusions: As with other studies, our studies demonstrate low rates of contraceptive use and high rates of interest in contraception use among women who use drugs. The PIS tool was completed by all women to whom it was offered, suggesting high levels of patient acceptability. Integration of a PIS tool was effective in identifying women with contraceptive needs and was acceptable to women.
- 10 February 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (3) , 754-758
Open AccessIntegrating routine screening for pregnancy intention and contraceptive use into care of women who use alcohol or other drugs
Introduction: There are high rates of unplanned pregnancy and low rates of contraceptive use in women with substance use disorders. Women who use drugs experience many barriers to health. In addiction treatment services in New South Wales, Australia, patients undergo routine health screening on treatment entry and annually thereafter. An integrated pregnancy and contraceptive screening tool was developed. The aim of this cross‐sectional study was to report the feasibility and preliminary outcomes of this tool.Methods: A pregnancy intention screening (PIS) tool was developed and integrated into the electronic medical record and the annual routine screening. This tool consisted of four yes/no questions about current pregnancy, future pregnancy plans and contraceptive use. Responses to these questions are reported. Descriptive statistics were used to report demographic and outcome data.Results: One hundred women were offered and completed the survey. There were low rates of effective or highly effective contraceptive use (24.5 percent of eligible participants). Seventy‐four percent of participants wanted further information on contraception.Discussion and Conclusions: As with other studies, our studies demonstrate low rates of contraceptive use and high rates of interest in contraception use among women who use drugs. The PIS tool was completed by all women to whom it was offered, suggesting high levels of patient acceptability. Integration of a PIS tool was effective in identifying women with contraceptive needs and was acceptable to women.